MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2025.128142

Медицинская библиотека · Vaccine · 2025

Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study.

Nonboe Mette Hartmann, Napolitano George, Schroll Jeppe Bennekou, Andersen Berit, Christiansen Sanne, Frandsen Anna Poulsgaard, Pedersen Helle, Lynge Elsebeth, Bonde Jesper, Høgdall Estrid

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The introduction of prophylactic HPV vaccination has significantly reduced vaccine-type HPV infections and is reshaping the landscape of cervical cancer prevention. As vaccinated cohorts enter screening age, understanding the genotype-specific risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) is critical for adapting screening strategies.

AIM: To compare HPV genotype-specific detection rates of histologically confirmed CIN2+ between vaccinated and unvaccinated women in Denmark's Trial23 cohort, with over seven years of follow-up.

METHOD: This population-based cohort study included 15,668 women born in 1994 who were offered HPV vaccination with the 4-valent vaccine in 2008 and entered Danish screening age in 2017 In our cohort, 95 % were vaccinated and 5 % were unvaccinated. The primary endpoints of this study were HPV-type-specific incident CIN2+ cases. The first histological biopsy sample diagnosed with CIN2+ in 2017-2023 was retrieved for HPV genotyping with the Seegene Allplex HPV28. Cox proportional hazards models estimated hazard ratios (HRs) for CIN2+ outcomes by hierarchically grouped HPV genotypes.

RESULTS

Among vaccinated women, the incidence of CIN2+ was 5.3 per 1000 person-years, compared to 12.1 per 1000 person-years in unvaccinated women (HR: 0.44; 95 % CI: 0.34-0.57). Vaccination was associated with a 95 % reduction in HPV16/18-related CIN2+ (HR: 0.05; 95 % CI: 0.03-0.09). A similar, but non-significant, trend of a 32 % risk of CIN2+ for HPV31/33/45/52/58 was found, with an adjusted HR of 0.68 (95 % CI: 0.43-1.09). For CIN2+ associated with other high-risk HPV types, the HR was 0.70 (95 % CI 0.35-1.37).

CONCLUSION

HPV16/18 vaccination reduced the risk of HPV16/18-related CIN2+ lesions, but a substantial burden remained from non-vaccine high-risk types. The substantial protection against HPV16/18-related CIN2+ and the consequential shift in HPV genotype distribution of CIN2+ among vaccinated women underline the need for adaptation of screening strategies.

Для цитирования: Nonboe Mette Hartmann, Napolitano George, Schroll Jeppe Bennekou, Andersen Berit, Christiansen Sanne, Frandsen Anna Poulsgaard, Pedersen Helle, Lynge Elsebeth, Bonde Jesper, Høgdall Estrid. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study.. Vaccine. 2025. DOI: 10.1016/j.vaccine.2025.128142.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.